Publications

Pooled extended-survival data from two trials including formerly untreated 563 patients who had received BRAF inhibitor dabrafenib plus MEK inhibitor trametinib in the COMBI-d and COMBI-v trials were investigated by the experts in order to determine, in metastatic melanoma, five-year outcomes with dabrafenib plus trametinib.

This retrospective cohort study was undertaken to determine if smoking was correlated with a higher rate of sentinel lymph node (SLN) metastasis and worse survival in cutaneous melanoma patients using a propensity score matching analysis.

Via this meta-analysis, researchers assessed the activity and efficacy of the following strategies to treat patients with melanoma brain metastases: targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy (CRI) or not in combination.

Please click on the link to see a list of melanoma journal citations the crossed the MRV desk this month.